BOT - Anything but charting, page-9295

No, Sofdra side effects are nothing like Qbrexza. You need to read the detail in the studies.

Also, whilst online patients (waiting patients, as nobody is using it yet) presently MAY see Sofdra as 'just another' antichlorinergic, they haven't experienced it or seen the reviews by actual users. This will be a key difference. Also the International Hyperhidrosis Society will be directly emailing its 50,000 deep database concerning Sofdra, so I expect there will be a lot more awareness soon.

Similarly, it has been in use in Japan for a couple of years now, and no issues raised there with side effects, and evidence of very good sales to boot.

The clinical study showed Sofdra was 30-40% more effective than Qbrexza and 85% of participants had a clinically meaningful outcome. Much better than Qbrexza.

It will take some time to launch, but if we could raise a stupendous sum in a tough market like this one, say $70m to promote, launch and distribute this 'exact same product', them maybe we could be onto something. Oh wait...